Inhibition of rhotekin exhibits antitumor effects in lung cancer cells.

摘要: Lung cancer is the leading cause for cancer-related death, however, pathogenesis mechanism poorly understood. Although rhotekin (RTKN) gene has been reported to encode an effector Rho protein that critical roles in regulating cell growth, role of RTKN lung not investigated. In clinical patient tumor samples, we identified expression level was significantly higher tissues compared adjacent normal tissues. To investigate molecular mechanisms cancer, established stable knock-down A549 and SPC-A-1 adenocarcinoma lines using lentiviral transfection shRNA evaluated antitumor effects. The results showed inhibited viability, induced S phase arrest increased apoptosis. addition, invasion adhesion. Further analysis promoting factors cyclin-dependent kinase (CDK)1 CDK2 levels were decreased cells, DNA replication initiation complex proteins Minichromosome maintenance (MCM)2 MCM6 as well cells. These indicated associated with clinic samples exerted anticancer activity cells through inhibiting cycle progression machinery. findings suggest inhibition may be a novel therapeutic strategy adenocarcinoma.